Skip to main content

Table 3 A brief overview of studies based on MSCs-exosomes in musculoskeletal disorders

From: A paradigm shift in cell-free approach: the emerging role of MSCs-derived exosomes in regenerative medicine

Condition

Sources

Main result

Refs.

OA

BM

OA rescue by suppressing inflammatory cytokines and also NLRP3 inflammasome activation by MSCs-exosomesin a rabbit model

[167]

IDD

BM

Modulation of endoplasmic reticulum stress and inhibition of excessive nucleus pulposus cell apoptosis by inducing AKT and ERK signaling in rat models by MSCs-exosomes

[168]

Osteoporosis

iPS-MSCs

Recovery of critical-sized bone defects by improved angiogenesis and osteogenesis by MSCs-exosomesin osteoporotic murine models

[169]

ONFH

iPS-MSCs

Inhibition of ONFH by exerting angiogenesis and inhibition of bone loss through the activation of PI3K/ AKT signaling pathway on endothelial cells elicited by iPS-MSCs-exosomesin ONFH mice model

[170]

OA

BM

Promotion of cartilage development and homeostasis through targeting WNT5A in mice by miR-92a-3p-enriched MSCs-exosomes

[122]

OA

ESCs-MSCs

OA rescue by regulation of the synthesis and degradation of chondrocyte ECM in mice models by ESCs-MSCs-exosomes

[118]

RA

BM

Reduction in joint destruction by inhibiting synoviocyte hyperplasia and angiogenesis by MSCs-exosomesin murine models

[124]

Cartilage defect

BM

Induction of cartilage repair in a rabbit model after combination therapy with MSCs-exosomesand hyaluronic acid

[171]

OA

Synovial

Improvement of the proliferation and migration of chondrocytes by Wnt5a and Wnt5b-enriched MSCs-exosomesmediated by YAP activation

[172]

DMD

PL

Reduction in creatine kinase and TGF-β levels and also promotion in utrophin levels in mice models by MSCs-exosomes

[173]

IVD

BM

Alleviation of IVD degeneration by miR-21 enriched MSCs-exosomesthrough inhibition of PTEN and consequently activation of PI3K/ AKT pathway

[174]

OA

BM

Alleviation of damage of the synovial fibroblasts via blocking PTGS2 elicited by miR-26a-5p enriched MSCs-exosomesin OA rat models

[175]

OA

BM

Re-induction of the expression of type II collagen, aggrecan, and also inhibition of MMP-13, ADAMTS5, and iNOS along with inhibition of macrophage activation in mice models by MSCs-exosomes

[176]

OA

AT

Protection of articular cartilage and alleviation of gait abnormalities by inhibition of mTOR in OA mice models by miR-100-5p enriched MSCs-exosomes

[117]

RA

BM

Suppression of fibroblast-like synoviocytes activation, migration, and invasion in vitro and recovery of arthritis and bone lesions in murine models in vivo by miR-320a-enriched MSCs-exosomes

[177]

  1. Micro RNA (miR), Bone marrow (BM), Adipose tissue (AT), Placental (PL), Embryonic stem cells (ESCs), Induced pluripotent stem cells (iPSCs), Osteoarthritis (OA), Intervertebral disc degeneration (IDD), Osteonecrosis of the femoral head (ONFH), Rheumatoid arthritis (RA), Duchene muscular dystrophy (DMD), Intervertebral disk (IVD) diseases, NLR family pyrin domain containing 3 (NLRP3), Extracellular signal-regulated kinase (ERK), Phosphatidylinositol-3-kinase (PI3K)/AKT, Wnt family member 5A (WNT5A), Extracellular matrix (ECM), Yes-associated protein (YAP), Transforming growth factor-beta (TGF-β), Phosphatase and tensin homolog (PTEN), Prostaglandin-endoperoxide synthase 2 (PTGS2), Matrix metalloproteinase type 13 (MMP-13), A disintegrin and metalloproteinase with thrombospondin motifs 5 (ADAMTS5), Inducible nitric oxide synthase (iNOS), Mammalian target of rapamycin (mTOR)